PET Biodistribution Study of 68Ga-PSMA-11 and 68Ga-FAPI-46

• Status: Not yet recruiting
• Trial end date: 2031-10-01
• Target enrollment: 30
• Participant gender: All

Summary

The tumor stroma supports tumor growth, promotes tumor aggressiveness and metastatic potential. Stroma targeting approaches have become an attractive goal in research and industry. Braking the tumor stroma barrier may make tumor cells more accessible for pharmacologic, immunologic, radioactive or cell-based therapies.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jonsson Comprehensive Cancer Center
• Collaborator: National Cancer Institute (NCI)

Criteria

Inclusion Criteria:

• Patients with the following cancer types:

• Breast cancer

• Colon cancer

• Esophageal cancer

• Gastric cancer

• Head and Neck cancer

• Lung cancer

• Ovarian cancer

• Pancreatic cancer

• Renal cancer

• Uterus Cancer

• Patients who are scheduled to undergo surgical resection of the primary tumor and/or metastasis.

• Patients are ≥ 18 years old at the time of the radiotracer administration.

• Patient can provide written informed consent.

• Patient is capable of complying with study procedures.

• Patient is able to remain still for duration of imaging procedure (up to one hour).

Exclusion Criteria:

Patient is pregnant or nursing Patient has underlying disease which, based on the judgement of the investigator, might interfere with the collection of high quality data